+
+
Stay Informed
TEER

TRICLIP™ TRICUSPID VALVE REPAIR CLINICAL DATA

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.

TEER

TRICLIP™ TRICUSPID
VALVE REPAIR
CLINICAL DATA

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.

THE FIRST CHOICE TO RESTORE THE TRICUSPID VALVE1

TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. bRIGHT and TRILUMINATE™ Pivotal Trials demonstrated the safety and effectiveness of TriClip TEER in the treatment of severe tricuspid regurgitation (TR).2-6

IMPROVING QUALITY OF LIFE
WITHOUT COMPROMISE2

The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER therapy was superior to medical therapy alone in improving quality of life and reducing tricuspid regurgitation.

Remarkable and Sustained TR Reduction2

TR Grade (Core Lab)

 

  • Extremely Safe Profile at 30-days2

    98.3%

    FREEDOM
    FROM MAEs

    0.6%

    NEW PACEMAKER
    IMPLANTATION

    0%

    DEVICE THROMBUS

    99.4%

    SURVIVAL

    0%

    NONELECTIVE CV
    SURGERY FROM
    DEVICE-RELATED AE

    0%

    DEVICE EMBOLIZATION

  • Significant Improvement in Quality of Life and Functional Status at 30-days2
  • Baseline Population Characteristics2

    71%

    OF PATIENTS HAD MASSIVE
    OR TORRENTIAL TR

    4.4±0.7cm

    TRICUSPID VALVE
    ANNULUS DIAMETER

    >35%

    OF PATIENTS WITH PRIOR
    VALVULAR INTERVENTION

    15%

    OF PATIENTS HAD A CRT, CRT-D, ICD,
    OR PERMANENT PACEMAKER

TRILUMINATE PIVOTAL TRIAL DATA CARD


Get the latest data from the TRILUMINATE Pivotal Trial in a one-pager PDF format.
 

GET DATA CARD

PROVEN ACROSS A BROAD
RANGE OF ANATOMIES7,8

The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.

Designed to Maximize TR Reduction7

TR Grade (Core Lab)

 

  • Successfully Treated a Broad Range of Anatomies8
  • Proven Durability Backed by Clinical Data7

    NYHA Functional Class

    KCCQ - OS

  • TriClip TEER demonstrated Procedural Success and a Strong Safety Profile5

    HIGH PROCEDURAL
    SUCCESS

    98%

    Implant
    sucess rate

    SHORT
    DEVICE TIME
     

    78±41

    Minutes

    HIGH SAFETY
    PROFILE
     

    99%

    Freedom
    from MAEs



    99.7% survival at 30 days

    1.3% reintervention

    0% embolization

     

bRIGHT STUDY DATA CARD


Get the latest data from the bRIGHT Study in a one-pager PDF format.
 

GET DATA CARD

PROVEN SAFETY AND EFFECTIVENESS

The TRILUMINATE™ Trial proved that TriClip TEER safely and effectively reduces TR and HF hospitalizations. 

93%

SURVIVAL
AT 1 YR3

100%

IMPLANT
SUCCESS4

91%

ACUTE PROCEDURAL
SUCCESS RATE4

0%

STROKE4

0%

CONVERSION TO
SURGERY4

  • Significant and Durable TR Reduction4

    Durable reduction in tricuspid regurgitation (TR)

    Durable reduction in tricuspid regurgitation (TR) for TriClip TEER System clinical study
  • Significant improvement in function and quality of life3

    Durable improvements in NYHA

    Durable improvements in NYHA for TriClip TEER System clinical study


    20 Points significant improvement in KCCQ-OS health-related quality of life at one-year

  • TriClip TEER demonstrated a high safety profile4

    High survival in a
    fragile patient population

    93%

    Survival
    at 1 year

     

    Low rates of
    major adverse events

    93%

    Freedom from MAEs
    at 1 year

  • Significant reduction in hospitalizations4

    Reduced hospitalization rate
     

    Reduced hospitalization rate for TriClip TEER System clinical study

TRILUMINATE TRIAL DATA CARD


Get the latest data from the TRILUMINATE Trial in a one-pager PDF format.
 

GET DATA CARD

MAT-2006556 v9.0 | Item approved for OUS use only.

References
  1. Data on file at Abbott.
  2. Sorajja P, Whisenant B, Hamid N, et al. TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation.” Presented at ACC; March 4, 2023; New Orleans, LA; USA.
  3. von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021.
  4. Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229-239.
  5. Lurz P, Lapp H, Schueler R, et al. Real-world outcomes for tricuspid edge-to-edge repair: initial 30-day results from the TriClip™ bRIGHT Study. Presented at: EuroPCR; May 17-20, 2022; Paris, France.
  6. Nickenig G., Weber M., Lurz P., et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019; 394 (10213): 2002-2011.
  7. Lurz P, Schmitz T, Bekeredjian R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 1 Year Outcomes from the bRIGHT trial. Presented at PCR London Valves; November 27-29, 2022; London, England.
  8. Lurz P et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results with TriClip™ G4 from the bRIGHT Study Presented at PCR London Valves 2022.
Abbott Logo

Follow Abbott

Copyright © 2024 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v17.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+